Johnson & Johnson’s $2.1bn acquisition of bispecific biotechs and Eli Lilly’s IL-13 inhibitor approval for Atopic Dermatitis underscores the fierce race to bring best-in-class therapies for immuno-inflammatory skin diseases to market.

As dermatology attracts a major wave of investment, large unmet need and disease heterogeneity discoveries make Galderma’s late-stage clinical results powerful and justify Incyte’s strategic prioritization of dermatology programs.

The 8th Dermatology Drug Development Summit is the pivotal event for advancing immuno-inflammatory drug pipelines and connecting prominent industry stakeholders.

Featuring late-breaking clinical data, immersive workshops on Hidradenitis Suppurativa, JAK inhibitors and Indication Expansion, along with specialized tracks designed for Discovery & Translational and Clinical & Commercialization experts. Attendees will gain the insights needed to turn cutting-edge R&D into transformative therapies.

This November, join 130+ biopharma and investment experts from leading organizations like Johnson & Johnson, AbbVie, Alys Pharmaceuticals, Incyte, Sanofi and LEO Pharma for three days of networking and discussing the latest dermatology innovations, like targeting OX-40, oral mAbs, siRNA and more!

Whether you're a C-Level executive or advancing drug programs, this is your opportunity to shape the future of dermatology treatments and improve patient outcomes!

Event link here.